Acute inflammatory demyelinating polyneuropathy after treatment with pegylated interferon alfa-2a in a patient with chronic hepatitis C virus infection: A case report

被引:0
作者
Lahbabi M. [1 ]
Ghissassi M. [2 ]
Belahcen F. [2 ]
Ibrahimi S.A. [1 ]
Aqodad N. [1 ]
机构
[1] Gastroenterology Unit, Hospital University Hassan II, Fez
[2] Neurology Unit, Hospital University Hassan II, Fez
关键词
Inflammatory demyelinating polyneuropathy; Neuropathy; PEGylated interferon; Viral hepatitis C infection;
D O I
10.1186/1752-1947-6-278
中图分类号
学科分类号
摘要
Introduction: The combination of polyethylene glycol (PEG)ylated interferon (pegylated interferon) and ribavirin has been shown to be an effective treatment for chronic hepatitis C virus. In general, common side effects related to this combination therapy are mild and are well tolerated. However, peripheral neuropathy including demyelinating polyneuropathy related to PEG-interferon α2a (pegylated interferon alfa-2a) is extremely rare. In the literature, only one case of acute inflammatory demyelinating polyneuropathy related to PEG-interferon α2a has been published previously. Case presentation: To the best of our knowledge we present only the second case of acute inflammatory demyelinating polyneuropathy related to PEG-interferon α2a, occurring in a 63-year-old Caucasian man. He developed tingling, numbness, and weakness of his upper and lower extremities with acute neurological deficits after five weeks of a combination therapy with PEG-interferon α2a and ribavirin for chronic hepatitis C virus infection. His clinical course, neurological findings, and his electromyogram results were all consistent with acute inflammatory demyelinating polyneuropathy. Our patient recovered completely after interferon was stopped and symptomatic treatment and a further electromyogram showed a disappearance of neuropathy. Four weeks later, PEG-interferon α2a was reintroduced with a gradually increasing dose without any reappearance of neurological symptoms allowing hepatitis C seroconversion. Conclusions: Recognition of this rare yet possible presentation is important for early and accurate diagnosis and treatment. This case report also suggests that the reintroduction of PEGylated interferon in patients who had presented with acute inflammatory demyelinating polyneuropathy related to interferon α may be safe, but this must be confirmed by further studies. © 2012 Lahbabi et al.; licensee BioMed Central Ltd.
引用
收藏
相关论文
共 50 条
[41]   A randomized, open-label, multicenter study evaluating the efficacy of peginterferon alfa-2a versus interferon alfa-2a, in combination with ribavirin, in naive and relapsed chronic hepatitis C patients [J].
Nevens, F. ;
Van Vlierberghe, H. ;
D'Heygere, F. ;
Delwaide, J. ;
Adler, M. ;
Henrion, J. ;
Lenaerts, A. ;
Hendliszs, A. ;
Michielsen, P. ;
Bastens, B. ;
Brenard, R. ;
Laureys, A. .
ACTA GASTRO-ENTEROLOGICA BELGICA, 2010, 73 (02) :223-228
[42]   Treatment of chronic hepatitis C virus infection after liver transplantation [J].
Agarwal, Kosh ;
Barnabas, Ashley .
DIGESTIVE AND LIVER DISEASE, 2013, 45 :S349-S354
[43]   Impact of pegylated interferon alfa-2a and ribavirin on hepatic fibrosis in liver transplant patients with recurrent hepatitis C: An open-label series [J].
Mukherjee, Sandeep ;
Lyden, Elizabeth .
HEPATO-GASTROENTEROLOGY, 2006, 53 (70) :561-565
[44]   Weekly Pegylated Interferon α-2b vs daily Interferon a-2b versus standard regimen of Interferon a-2b in the treatment of patients with chronic hepatitis C virus infection [J].
Horsmans, Y. ;
Colle, I. ;
Van Vlierberghe, H. ;
Langlet, Ph. ;
Adler, M. ;
Bourgeois, N. ;
Brenard, R. ;
Michielsen, P. ;
Goossens, A. ;
Bruckers, L. .
ACTA GASTRO-ENTEROLOGICA BELGICA, 2008, 71 (03) :293-297
[45]   Pegylated interferon-alpha2b plus ribavirin for the treatment of chronic hepatitis C virus genotype 4 infection in patients with normal serum ALT [J].
Al-Ali, Jaber ;
Siddique, Iqbal ;
Varghese, Rosh ;
Hasan, Fuad .
ANNALS OF HEPATOLOGY, 2012, 11 (02) :186-193
[46]   Analysis of variables and interactions among variables associated with a sustained virological response to pegylated interferon alfa-2a plus ribavirin in hepatitis C virus genotype 3-infected patients [J].
Aziz, Hafsa ;
Raza, Abida ;
Waheed, Yasir ;
Gill, Uzma ;
Gill, Muzaffar Lateef .
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2012, 16 (08) :E597-E602
[47]   Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients [J].
Dominguez, Stephanie ;
Ghosn, Jade ;
Valantin, Marc-Antoine ;
Schruniger, Aurelie ;
Simon, Anne ;
Bonnard, Philippe ;
Caumes, Eric ;
Pialoux, Gilles ;
Benhamou, Yves ;
Thibault, Vincent ;
Katlama, Christine .
AIDS, 2006, 20 (08) :1157-1161
[48]   Treatment of Acute Hepatitis C Infection with Pegylated Interferon and Ribavirin in Patients Coinfected with Human Immunodeficiency Virus: A Systematic Review and Meta-Analysis [J].
Zhang, Bing ;
Nguyen, Nghia H. ;
Yee, Brittany E. ;
Yip, Benjamin ;
Ayoub, Walid S. ;
Lutchman, Glen A. ;
Nguyen, Mindie H. .
INTERVIROLOGY, 2015, 58 (04) :242-249
[49]   Clinical experience with nonstandard doses of interferon Alfa-2b and ribavirin in the treatment of chronic Hepatitis C infection: A retrospective analysis [J].
Hare, CB ;
Loveland, JJ ;
Chu, A ;
Morris, JA ;
Gotz, V ;
Klaskala, W .
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 2005, 66 (05) :433-450
[50]   Hepatitis C virus relapse was suppressed by long-term self-injection of low-dose interferon in patients with chronic hepatitis C after pegylated interferon plus ribavirin treatment [J].
Takashima, Tomoyuki ;
Enomoto, Hirayuki ;
Ninomiya, Toshiaki ;
Kim, Soo Ryang ;
Okushin, Hiroaki ;
Sugano, Masahiko ;
Imoto, Susumu ;
Yano, Yoshihiko ;
Ooka, Teruji ;
Seo, Yasushi ;
Kasugai, Hiroshi ;
Muramatsu, Akira ;
Jomura, Hisato ;
Shimomura, Soji ;
Shindo, Michiko ;
Nakamura, Hideji ;
Aizawa, Nobuhiro ;
Iwata, Yoshinori ;
Saito, Masaki ;
Imanishi, Hiroyasu ;
Iijma, Hiroko ;
Nishiguchi, Shuhei .
HEPATOLOGY RESEARCH, 2014, 44 (06) :597-607